

UCSF

UC San Francisco Previously Published Works

Title

Translational studies in the ex vivo human lung

Permalink

<https://escholarship.org/uc/item/2hv8s258>

Journal

Respiratory Investigation, 52(4)

ISSN

2212-5345

Authors

Sakuma, T
Matthay, MA

Publication Date

2014

DOI


10.1016/j.resinv.2014.06.001

Peer reviewed



Contents lists available at ScienceDirect

Respiratory Investigation

journal homepage: www.elsevier.com/locate/resinv

Editorial

Translational studies in the *ex vivo* human lung

Over two decades, considerable progress has been made in the basic and clinical research of alveolar fluid clearance under normal and pathological conditions using the *ex vivo* human lung model. Alveolar fluid clearance describes the function of alveolar epithelial cells to remove alveolar fluid from the alveolar space across the alveolar epithelial barrier. In hydrostatic pulmonary edema, as well as in acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), alveolar fluid clearance drives the resolution of pulmonary edema. Although there are several experimental preparations in animals and in *in vitro* models to elucidate the mechanisms responsible for alveolar fluid clearance, an experimental model using the *ex vivo* human lung is valuable for assessment prior to clinical trials for lung diseases. The human lung preparation was originally designed by thoracic surgeons in Sendai Kosei Hospital and Tohoku University, Japan, in collaboration with Dr. Matthay in University of California, San Francisco [1].

Prior to the development of *ex vivo* human lung model, an analysis of serial samples of distal bronchial edema fluid from patients with pulmonary edema demonstrated the role of active transport in the resolution of alveolar edema fluid for the first time [2]. However, it was difficult to test the effect of agents on the rate of alveolar fluid clearance in the clinical setting. In addition, another unresolved issue was the species differences in the effect of beta-adrenergic agonists that would be a candidate of therapy for accelerating the resolution of pulmonary edema in patients.

Because of the results of an experimental study that alveolar fluid clearance occurred in the absence of any pulmonary perfusion, the *ex vivo* human lung preparation was designed in the excised human lungs from patients with lung cancer [2]. The preparation demonstrated new findings. Alveolar fluid clearance in the human lung depends on amiloride-sensitive sodium channel and ouabain-sensitive Na-K ATPase, components of active ion transport in the *ex vivo* human lung. Terbutaline, a beta-adrenergic agonist, stimulated alveolar fluid clearance *via* the adrenergic receptor and the sodium channel. Although the basic mechanisms responsible for alveolar fluid clearance were determined in the *ex vivo* human lung, there were limitations because of the absence of pulmonary perfusion.

Since the worldwide low utilization of potential donor lungs is persistent, the capability of alveolar fluid clearance in the donor lungs rejected for lung transplantation was used to assess the rejected donor lungs [3]. Then, Frank et al.

developed a new human lung preparation with pulmonary perfusion. Lungs from brain-dead organ donors that were rejected for lung transplantation were provided by the Northern California Transplant Donor Network [4]. The study indicated that pulmonary perfusion improved the rate of alveolar fluid clearance in the human lung and the possibility to deliver test substances and therapeutic agents through the vasculature.

Recently, cell therapy using human mesenchymal stem cells (MSCs) has become a promising candidate for acute lung diseases, particularly for ALI/ARDS. Lee et al. used the *ex vivo* human lung preparation and demonstrated that treatment with allogeneic bone marrow-derived human MSCs improved lung endothelial barrier permeability and restored alveolar fluid clearance [5,6]. Interestingly, there are cell contact-dependent and independent mechanisms in the treatment of MSCs that suggest the capability of rescue in both injured pulmonary endothelium and alveolar epithelium [7].

There is only one effective to reduce mortality for ARDS, low tidal volume lung protective ventilation [8]. Thus, new treatments are needed. The current National Heart, Lung and Blood Institute (NHLBI) portfolio has focused in part on basic research to build fundamental knowledge of the role of stem/progenitor cells in lung disease and injury/repair [9]. As translational work progresses to assess efficacy and safety, studies in the *ex vivo* human lung can play an important role in the basic science studies and the preclinical work for clinical trials, and will continue to be needed more to test efficacy and safety of new treatments.

REFERENCES

- [1] Matthay MA, Wiener-Kronish JP. Intact epithelial barrier function is critical for the resolution of alveolar edema in humans. *Am Rev Respir Dis.* 1990;142:1250–7.
- [2] Sakuma T, Okaniwa G, Nakada T, et al. Alveolar fluid clearance in the resected human lung. *Am J Respir Crit Care Med.* 1994;150:305–10.
- [3] Ware LB, Wang Y, Fang X, et al. Assessment of lungs rejected for transplantation and implications for donor selection. *Lancet* 2002;360:619–20.
- [4] Frank JA, Briot R, Lee JW, et al. Physiological and biochemical markers of alveolar epithelial barrier dysfunction in perfused human lungs. *Am J Physiol Lung Cell Mol Physiol* 2007;293:L52–59.
- [5] Lee JW, Fang X, Gupta N, et al. Allogeneic human mesenchymal stem cells for treatment of *E. coli* endotoxin-induced acute lung

- injury in the ex vivo perfused human lung. *Proc Natl Acad Sci USA* 2009;106:16357–62.
- [6] Lee JW, Krasnodembskaya A, McKenna DH, et al. Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. *Am J Respir Crit Care Med* 2013;187:751–60.
- [7] Bhattacharya J, Matthay MA. Regulation and repair of the alveolar-capillary barrier in acute lung injury. *Annu Rev Physiol* 2013;75:593–615.
- [8] Matthay MA, Ware LB, Zimmerman GA. The acute respiratory distress syndrome. *J Clin Invest* 2012;122:2731–40.
- [9] Matthay MA, Anversa P, Bhattacharya J, et al. Cell therapy for lung diseases. Report from an NIH-NHLBI workshop. *Am J Respir Crit Care Med* 2013;188:370–5.

T. Sakuma*

*Department of Thoracic Surgery, Kanazawa Medical University,
Uchinada, Ishikawa, Japan*

M.A. Matthay

*Department of Anesthesia and Medicine, University of California,
San Francisco, CA, USA*

*Corresponding author.